Search

Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance

Publication: Journal Article

Wei, G., D. Twomey, J. Lamb, K. Schlis, J. Agarwal, R. W. Stam, J. T. Opferman, et al. 2006. “Gene Expression-Based Chemical Genomics Identifies Rapamycin As a Modulator of MCL1 and Glucocorticoid Resistance”. Cancer Cell 10: 331-42.

Publication: Journal Article

Yu, C., A. M. Mannan, G. M. Yvone, K. N. Ross, Y. L. Zhang, M. A. Marton, B. R. Taylor, et al. 2016. “High-Throughput Identification of Genotype-Specific Cancer Vulnerabilities in Mixtures of Barcoded Tumor Cell Lines”. Nat Biotechnol 34: 419-23.

Publication: Journal Article

Parikh, A. R., I. Leshchiner, L. Elagina, L. Goyal, C. Levovitz, G. Siravegna, D. Livitz, et al. 2019. “Liquid versus Tissue Biopsy for Detecting Acquired Resistance and Tumor Heterogeneity in Gastrointestinal Cancers”. Nat Med 25: 1415-21.

Publication: Journal Article

Peck, D., E. D. Crawford, K. N. Ross, K. Stegmaier, T. R. Golub, and J. Lamb. 2006. “A Method for High-Throughput Gene Expression Signature Analysis”. Genome Biol 7: R61.

Publication: Journal Article

Pikman, Y., B. H. Lee, T. Mercher, E. McDowell, B. L. Ebert, M. Gozo, A. Cuker, et al. 2006. “MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis With Myeloid Metaplasia”. PLoS Med 3: e270.

Publication: Journal Article

Raj, L., T. Ide, A. U. Gurkar, M. Foley, M. Schenone, X. Li, N. J. Tolliday, et al. 2018. “Retraction Note: Selective Killing of Cancer Cells by a Small Molecule Targeting the Stress Response to ROS”. Nature 561: 420.

Publication: Journal Article

Ramaswamy, S., P. Tamayo, R. Rifkin, S. Mukherjee, C. H. Yeang, M. Angelo, C. Ladd, et al. 2001. “Multiclass Cancer Diagnosis Using Tumor Gene Expression Signatures”. Proc Natl Acad Sci U S A 98: 15149-54.

Publication: Journal Article

Slabicki, M., Z. Kozicka, G. Petzold, Y. D. Li, M. Manojkumar, R. D. Bunker, K. A. Donovan, et al. 2020. “The CDK Inhibitor CR8 Acts As a Molecular Glue Degrader That Depletes Cyclin K”. Nature 585: 293-97.

Publication: Journal Article

Ebert, B. L., N. Galili, P. Tamayo, J. Bosco, R. Mak, J. Pretz, S. Tanguturi, et al. 2008. “An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome”. PLoS Med 5: e35.

Publication: Journal Article

Enache, O. M., V. Rendo, M. Abdusamad, D. Lam, D. Davison, S. Pal, N. Currimjee, et al. 2020. “Cas9 Activates the P53 Pathway and Selects for P53-Inactivating Mutations”. Nat Genet 52: 662-68.